Market Cap 3.42B
Revenue (ttm) 196.54M
Net Income (ttm) -140.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -71.25%
Debt to Equity Ratio 0.69
Volume 2,876,100
Avg Vol 2,413,742
Day's Range N/A - N/A
Shares Out 122.49M
Stochastic %K 76%
Beta 1.97
Analysts Strong Sell
Price Target $31.00

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 418 5006
Address:
3027 Townsgate Road, Suite 300, Westlake Village, United States
PrivateProfiteering
PrivateProfiteering Nov. 21 at 4:29 AM
$ARQT is currently trading at $27.33, showing a strong upward momentum as indicated by its RSI of 59.37, which suggests bullish sentiment but is approaching overbought territory. The price is well above both the 30-day moving average (MA30) of 23.22 and the 50-day moving average (MA50) of 21.34, indicating a solid bullish trend. The recent high of $28.96 within the last 60 days provides a resistance level, while the low of $15.1 offers a clear support base. For a trade plan, consider entering at $27.50, with a stop loss set at $26.00 to manage risk. Target 1 can be set at $28.50, just below the 60D high, and Target 2 at $29.00, anticipating a breakout. This plan leverages the current bullish indicators and the established high-low range for potential gains. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 21 at 2:22 AM
1ightning® Options Trade Alert (Actionable) | Buy $ARQT Dec 19 $30 Call | Enter: $1.04 Exit: $1.84 | Profit: 77.76% ROI | https://1ightning.com
0 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 20 at 9:45 AM
$ARQT is currently trading at $25.0, showing a strong upward momentum with an RSI of 69.51, indicating it is nearing overbought territory. The 30-day moving average (MA30) is at $22.34, and the 50-day moving average (MA50) is at $20.58, both suggesting a bullish trend as the price is well above these averages. The 60-day high of $27.08 provides a resistance level, while the 60-day low of $15.1 indicates significant support. Given the current metrics, the directional bias is bullish, but caution is warranted due to the high RSI. A suggested entry point could be around $24.50 to capture potential upward movement while managing risk. A stop loss can be set at $23.00 to limit losses. Target 1 can be set at $27.00, near the recent high, and Target 2 at $28.00 for a more aggressive approach. Monitor the price action closely for any signs of reversal. https://privateprofiteers.com
0 · Reply
Chasetae
Chasetae Nov. 20 at 12:13 AM
$ARQT finally getting the respect she deserves.
0 · Reply
Dr_Stoxx
Dr_Stoxx Nov. 19 at 11:56 PM
0 · Reply
Iightning
Iightning Nov. 19 at 11:47 PM
1ightning® Options Trade Alert (Actionable) | Buy $ARQT Dec 19 $30 Call | Enter: $1.04 Exit: $1.84 | Profit: 77.76% ROI | https://1ightning.com
0 · Reply
dekkoe
dekkoe Nov. 19 at 8:04 PM
$ARQT 30 next week.👍🏼
0 · Reply
FATSTAX
FATSTAX Nov. 19 at 4:01 PM
$SPY $ARQT Monthly Pros = white candles Short something else.
0 · Reply
RonIsWrong
RonIsWrong Nov. 19 at 3:18 PM
$ARQT beauty!!
0 · Reply
Stonksmann
Stonksmann Nov. 19 at 11:38 AM
$ARQT 38-40 in play? Likely a correction prior though
0 · Reply
Latest News on ARQT
Arcutis to Present at Upcoming Investor Conferences

Oct 27, 2025, 4:00 PM EDT - 24 days ago

Arcutis to Present at Upcoming Investor Conferences


Arcutis Biotherapeutics: Another Approval Under Their Belt

Jun 25, 2025, 4:43 AM EDT - 5 months ago

Arcutis Biotherapeutics: Another Approval Under Their Belt


Arcutis: Out Of The Woods, Ready For Commercialization

Jun 12, 2025, 11:57 PM EDT - 5 months ago

Arcutis: Out Of The Woods, Ready For Commercialization


Arcutis Announces Chief Financial Officer Transition

Apr 10, 2025, 4:30 PM EDT - 8 months ago

Arcutis Announces Chief Financial Officer Transition


Arcutis and Padagis Agree to Stay Patent Lawsuit

Apr 2, 2025, 1:16 PM EDT - 8 months ago

Arcutis and Padagis Agree to Stay Patent Lawsuit


Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

Mar 25, 2025, 8:16 AM EDT - 8 months ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

TNXP


PrivateProfiteering
PrivateProfiteering Nov. 21 at 4:29 AM
$ARQT is currently trading at $27.33, showing a strong upward momentum as indicated by its RSI of 59.37, which suggests bullish sentiment but is approaching overbought territory. The price is well above both the 30-day moving average (MA30) of 23.22 and the 50-day moving average (MA50) of 21.34, indicating a solid bullish trend. The recent high of $28.96 within the last 60 days provides a resistance level, while the low of $15.1 offers a clear support base. For a trade plan, consider entering at $27.50, with a stop loss set at $26.00 to manage risk. Target 1 can be set at $28.50, just below the 60D high, and Target 2 at $29.00, anticipating a breakout. This plan leverages the current bullish indicators and the established high-low range for potential gains. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 21 at 2:22 AM
1ightning® Options Trade Alert (Actionable) | Buy $ARQT Dec 19 $30 Call | Enter: $1.04 Exit: $1.84 | Profit: 77.76% ROI | https://1ightning.com
0 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 20 at 9:45 AM
$ARQT is currently trading at $25.0, showing a strong upward momentum with an RSI of 69.51, indicating it is nearing overbought territory. The 30-day moving average (MA30) is at $22.34, and the 50-day moving average (MA50) is at $20.58, both suggesting a bullish trend as the price is well above these averages. The 60-day high of $27.08 provides a resistance level, while the 60-day low of $15.1 indicates significant support. Given the current metrics, the directional bias is bullish, but caution is warranted due to the high RSI. A suggested entry point could be around $24.50 to capture potential upward movement while managing risk. A stop loss can be set at $23.00 to limit losses. Target 1 can be set at $27.00, near the recent high, and Target 2 at $28.00 for a more aggressive approach. Monitor the price action closely for any signs of reversal. https://privateprofiteers.com
0 · Reply
Chasetae
Chasetae Nov. 20 at 12:13 AM
$ARQT finally getting the respect she deserves.
0 · Reply
Dr_Stoxx
Dr_Stoxx Nov. 19 at 11:56 PM
0 · Reply
Iightning
Iightning Nov. 19 at 11:47 PM
1ightning® Options Trade Alert (Actionable) | Buy $ARQT Dec 19 $30 Call | Enter: $1.04 Exit: $1.84 | Profit: 77.76% ROI | https://1ightning.com
0 · Reply
dekkoe
dekkoe Nov. 19 at 8:04 PM
$ARQT 30 next week.👍🏼
0 · Reply
FATSTAX
FATSTAX Nov. 19 at 4:01 PM
$SPY $ARQT Monthly Pros = white candles Short something else.
0 · Reply
RonIsWrong
RonIsWrong Nov. 19 at 3:18 PM
$ARQT beauty!!
0 · Reply
Stonksmann
Stonksmann Nov. 19 at 11:38 AM
$ARQT 38-40 in play? Likely a correction prior though
0 · Reply
Iightning
Iightning Nov. 19 at 8:02 AM
1ightning® Options Trade Alert (Actionable) | Buy $ARQT Dec 19 $30 Call | Enter: $1.04 Exit: $1.84 | Profit: 77.76% ROI | https://1ightning.com
0 · Reply
danaos
danaos Nov. 19 at 12:51 AM
$ARQT Overweight
0 · Reply
Chasetae
Chasetae Nov. 18 at 11:13 PM
$ARQT looking for $38
0 · Reply
lyonsa14
lyonsa14 Nov. 18 at 8:42 PM
$ARQT Possibly, of course one never knows. From the beginning, I expected this company to eventually be bought for $40-50 per share. Although, there seems to be a significant shift of money moving out of big tech and into other areas, including biotech which may be the main reason for the recent significant price appreciation. As a long-term biotech investor, I’ve been patiently waiting for this time with this stock as well as other biotech stocks I own. I’ve been in this stock many years and seen it drop all the way to $2, which I aggressively added to at this price.
1 · Reply
Dr_Stoxx
Dr_Stoxx Nov. 18 at 7:43 PM
$ARQT: WE ARE LONG THIS BEAUTY IN THE LIVE TRADING ROOM. MEMORIZE THIS CHART PATTERN: *POWER GAP ON EARNINGS OR SOME POSITIVE NEWS... *RETEST OF THE GAP... *RALLY ON GOOD VOLUME. IF YOU SEE ONE LIKE THIS, LET ME KNOW!
0 · Reply
ZManicItalian
ZManicItalian Nov. 18 at 7:35 PM
$ARQT 🤑🤙
0 · Reply
Artster25
Artster25 Nov. 18 at 7:11 PM
$ARQT last month up 30% ! I know they have recieved many recent approvals . That said it feels like something more going on . I have followed this stock for months & it rarely goes up a dollar plus a day like it has this week.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 18 at 5:45 PM
$ARQT is an amazing company. This morning ARQT announced another Zoryve sNDA submission was accepted by the FDA. This submission, for pediatric plaque psoriasis, marks its 4th or 5th regulatory submission. The point of this post is not to bash ARQT. Now at a ~$3.3B valuation, it has done everything right for shareholders. $SNDX market cap is roughly $1.5B which is meaningfully less than half of ARQT's market cap. Both hold cash that is slightly higher than debt. SNDX is oncology focused where ARQT is non-oncology The attachment compares ARQT analyst consensus revenue estimates to SNDX for the next 6 years. Notice the forecasts are nearly identical? ARQT reported 91% gross profit margins YTD where SNDX is at 96%. Again, this is not at all to bash ARQT but to highlight the disconnect to an oncology focused peer like SNDX. $XBI $IBB $NBI
0 · Reply
RonIsWrong
RonIsWrong Nov. 18 at 4:59 PM
$ARQT looking strong
1 · Reply
AdiKrononaut
AdiKrononaut Nov. 17 at 10:48 PM
0 · Reply
Johnny_Lever
Johnny_Lever Nov. 17 at 5:32 PM
$ARQT What a beauty of a chart! Repeatedly tagged the 21 ema on the way up.
0 · Reply
AdiDasRom
AdiDasRom Nov. 17 at 4:58 PM
0 · Reply